Company news

Relmada Therapeutics, Inc. news in 2022

Relmada Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder

December 6, 2022

Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

November 9, 2022

Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder

October 12, 2022

Relmada Therapeutics Announces Completion of Treatment in Company's Registrational Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for Major Depressive Disorder

September 19, 2022

Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results

August 10, 2022

Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder

August 8, 2022

Relmada Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022

August 4, 2022

Relmada Therapeutics Appoints Biopharmaceutical Marketing and Commercial Planning Veteran John Hixon as Head of Commercial

July 20, 2022

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

May 4, 2022

Relmada Therapeutics Announces Publication of REL-1017 Preclinical Data in Frontiers in Pharmacology

April 28, 2022

Relmada Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022

April 27, 2022

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results

March 22, 2022

Relmada Therapeutics to Report Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 23, 2022

March 15, 2022

Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Ketamine for Abuse Potential

February 22, 2022

Calls in 2022

Decks in 2022